STORM Therapeutics
Biotech · Cambridge, GB
Spin-out di Cambridge che sviluppa farmaci oncologici basati sull'epigenetica dell'RNA (inibitore METTL3).
Funding history
| Date | Round | Amount |
|---|
| Apr 2026 | Series C STORM Therapeutics closed a $56M Series C entirely from existing investors to start the Phase 2 trial of its oncology drug STC-15. | $56M |
Investors
Fast Track InitiativeIP GroupM VenturesPfizer VenturesTaiho VenturesUTokyo Innovation Platform
Similar companies in Biotech
Explore funding flow on EquityFlow →